Disc Medicine Initiated With an Outperform at Scotiabank
Disc Medicine Announces Presentation of New Data From Phase 1b Trial of DISC-0974 in Patients With Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week
Express News | Disc Medicine Announces Presentation of New Data From Phase 1B Trial of Disc-0974 in Patients With Chronic Kidney Disease (Ckd) and Anemia at 2024 American Society of Nephrology (Asn) Kidney Week
Express News | Cantor Fitzgerald Reiterates Overweight on Disc Medicine, Maintains $85 Price Target
Express News | Disc Medicine Expands Leadership Team With Appointment of Industry Veteran Steve Caffé, Md as Chief Regulatory Officer
Press Release: Disc Medicine Expands Leadership Team With Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer
Disc Medicine's Chief Medical Officer Sells Shares Worth Over $71k
H.C. Wainwright Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $70
Buy Rating Affirmed for Disc Medicine on Promising Drug Pipeline and Strategic Developments
Disc Medicine to Participate in Upcoming Investor Conferences
Disc Medicine Initiated at Overweight by Wells Fargo
Disc Medicine Price Target Announced at $75.00/Share by Wells Fargo
Wells Fargo Initiates Disc Medicine(IRON.US) With Buy Rating, Announces Target Price $75
Optimistic Outlook on Disc Medicine's Pipeline and Investment Potential
Analysts Offer Insights on Healthcare Companies: Immunocore Holdings (IMCR), Natera (NTRA) and Disc Medicine (IRON)
Companies Like Disc Medicine (NASDAQ:IRON) Are In A Position To Invest In Growth
Here's Why We're Not Too Worried About Disc Medicine's (NASDAQ:IRON) Cash Burn Situation
Express News | Wedbush Reiterates Outperform on Disc Medicine, Maintains $57 Price Target
Disc Medicine (IRON) Gets a Hold From Morgan Stanley
Disc Medicine (IRON) Receives a New Rating From Wedbush